

Optimising the continuum of care for patients with **ALK+ NSCLC**

12.00-13.00
Wednesday 13 April 2016
Room A, Palexpo
Geneva, Switzerland

Light refreshments will be served prior to the symposium

Chair's welcome

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**Optimising the continuum of care for patients with ALK+ NSCLC**'. The symposium will be held on Wednesday 13 April 2016 from 12.00 to 13.00, during the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

The discovery of *ALK* gene rearrangements in 2007 transformed both the testing and treatment landscape in NSCLC,^{1,2} and with the recent first-line approval of crizotinib, patients with advanced ALK+ NSCLC may now benefit from ALK-targeted therapy at the point of diagnosis.

During our symposium, we will discuss the importance of minimising molecular testing turnaround times in order to better inform first-line treatment decisions in NSCLC. Our faculty will review the latest data for ALK inhibitors and discuss how to provide the best continuum of care for patients with ALK+ NSCLC. Discussion points will include maximising clinical benefit with crizotinib, the management of brain metastases, resistance and sequencing of ALK inhibitors to maximise clinical outcome.

I look forward to welcoming you to Geneva and I hope you will join us for what promises to be an informative and engaging symposium.

Best regards,



Federico Cappuzzo, Chair
Director Medical Oncology Department
Istituto Toscano Tumori, Livorno, Italy

References:

- Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561-567.
- Rikova K, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 2007;131:1190-1203.

Programme

- 12.00 Welcome and introduction**
The importance of immediate, early molecular testing for first-line treatment decisions in NSCLC
Federico Cappuzzo, Chair (Italy)
- 12.10 Crizotinib: First-line treatment for patients with ALK+ NSCLC**
Benjamin Solomon (Australia)
- 12.25 Panel discussion**
All faculty
- 12.35 Continuum of care for ALK+ NSCLC: What should we do if resistance develops?**
Solange Peters (Switzerland)
- 12.50 Panel discussion**
All faculty
- 13.00 Meeting close**



Pfizer and Merck KGaA, Darmstadt, Germany, co-promote XALKORI (crizotinib) in the United States, Canada, Japan, China, Turkey, and five European Union countries (France, Germany, Italy, Spain, and the United Kingdom).

This meeting is organised and funded by Pfizer Oncology
© Pfizer Pharma GmbH. All rights reserved
February 2016. PP-XLK-EUR-0016